Trius Therapeutics Inc. (TSRX: Quote) Friday said it has obtained a committed equity financing facility under which it may from time to time sell up to $25 million of its registered common stock to Terrapin Opportunity L.P., over a 24-month period.
Trius is not obligated to utilize any of the $25 million facility and remains free to enter into and consummate other equity and debt financing transactions.
"This facility, combined with Trius' nearly $84 million in cash and investments at June 30, 2012, provides Trius with additional financing options as the Company prepares for the commercialization of tedizolid phosphate," said John Schmid, Chief Financial Officer of Trius.
Click here to receive FREE breaking news email alerts for Trius Therapeutics Inc. and others in your portfolio
by RTT Staff Writer
For comments and feedback: firstname.lastname@example.org